Likewise, antifibrotic therapy with losartan has been shown to decrease fibrous ECM and has gone through promising Phase II trials (58), and multiple early trials with FAK inhibitors are ongoing for PDA (e.g., NCT02758587, NCT04331041, NCT03727880; www.clinicaltrials.gov). The gene discussed is PTK2; the disease is Patent ductus arteriosus.